Page 51 - 17_Atti_SNO_2023_flip

Proceedings SNO “LXII Congresso Nazionale SNO”

corso sperimentazioni mirate a diverse mutazioni, come la Lefranc F, Clement PM, Dumont S, Sanson M, Bronnimann
mutazione SMO con l’inibitore SMO Vismodegib, la mu- C, Balaná C, Thon N, Lewis J, Mair MJ, Sievers P, Furtner J,
tazione Akt con l’inibitore AKT, Capivasertib, le alterazio- Pichler J, Bruna J, Ducray F, Reijneveld JC, Mawrin C,
ni CDKN2A con gli inibitori CDK4/6 e le mutazioni NF2 Bendszus M, Marosi C, Golfinopoulos V, Coens C, Gorlia T,
Weller M, Sahm F, Wick W. Trabectedin for recurrent WHO
con l’inibitore FAK GSK2256098 .
(8)
grade 2 or 3 meningioma: A randomized phase II study of the
EORTC Brain Tumor Group (EORTC-1320-BTG). Neuro
Oncol 2022; 24 (5): 755-767.
BIBLIOGRAFIA
5. Chamberlain MC. Hydroxyurea for recurrent surgery and ra-
1. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, diation refractory high-grade meningioma. J Neurooncol
Russell CA, Lucci L, Stevenson LL. Treatment of unre- 2012; 107 (2): 315-321.
sectable meningiomas with the antiprogesterone agent 6. Tollefsen SE, Solheim O, Mjønes P, Torp SH. Meningiomas and
mifepristone. J Neurosurg 1991; 74 (6): 861-866. somatostatin analogs: a systematic scoping review on current in-
2. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide sights and future perspectives. Int J Mol Sci 2023; 24 (5): 4793.
for treatment-resistant recurrent meningioma. Neurology 7. Graillon T, Sanson M, Campello C, Idbaih A, Peyre M,
2004; 62 (7): 1210-1212. Peyrière H, Basset N, Autran D, Roche C, Kalamarides M,
3. Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré
JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier
Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III A, Dufour H, Chinot OL. Everolimus and Octreotide for pa-
randomized trial of the antiprogestin agent Mifepristone in the tients with recurrent meningioma: results from the phase II
treatment of unresectable meningioma: SWOG S9005. J Clin CEVOREM Trial. Clin Cancer Res 2020; 26 (3): 552-557.
Oncol 2015; 33 (34): 4093-4098. 8. Graillon T, Tabouret E, Salgues B, Horowitz T, Padovani L,
4. Preusser M, Silvani A, Le Rhun E, Soffietti R, Lombardi G, Appay R, Farah K, Dufour H, Régis J, Guedj E, Barlier A,
Sepulveda JM, Brandal P, Brazil L, Bonneville-Levard A, Chinot O. Innovative treatments for meningiomas. Rev
Lorgis V, Vauleon E, Bromberg J, Erridge S, Cameron A, Neurol 2023; 179 (5): 449-463.

- 49 -